Ones To Watch News
Refine Search
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Oncology
California-based biopharma BridgeBio Pharma has announced the completion of a $200 million private financing of its former subsidiary, TheRas. 3 May 2024
Psychedelics
Philadelphia, USA-based Reunion Neuroscience, a company developing psychedelics for the treatment of mental health conditions, has announced the closing of a $103 million Series A financing. 3 May 2024
Pharmaceutical
US cancer drug developer Context Therapeutics saw its share close up 27.3% at $1.75 yesterday, after it revealed a financing deal. 3 May 2024
Biotechnology
New Jersey, USA-based PDS Biotechnology today announced the appointment of Stephan Toutain, as chief operating officer (COO), effective as of May 1, 2024. 2 May 2024
Biotechnology
mRNA specialist Moderna has opted to end its collaboration with fellow US biotech Metagenomi on primary hyperoxaluria type 1 (PH1). 2 May 2024
Pharmaceutical
Pivotal data for the novel KRAS G12C inhibitor glecirasib have been presented at the April ASCO Plenary Series. 2 May 2024
Biotechnology
San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second collaboration with Japanese drug major Astellas Pharma. 2 May 2024
Pharmaceutical
New Zealand-based AFT Pharmaceuticals has announced the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil. 2 May 2024
Biotechnology
UK clinical-stage biotech Barinthus Biotherapeutics, formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO). 1 May 2024
Biotechnology
Californian biotech Enlaza Therapeutics has raised $100 million in a series A financing led by J.P. Morgan Asset Management’s Private Capital division. 1 May 2024
Biotechnology
Japanese biotech PeptiDream edged up 3% to 2,081 yen today, after it announced an expansion of its peptide discovery collaboration with Swiss pharma giant Novartis. 1 May 2024
Biotechnology
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
Biotechnology
UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader company expansion. 1 May 2024
Pharmaceutical
Shares of US developer of rare neurological drugs Harmony Biosciences (Nasdaq: HRMY) rose more than 10% to $32.30 today, after it announced the acquisition of Epygenix Therapeutics. 30 April 2024
Pharmaceutical
X4 Pharmaceuticals has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis). 30 April 2024
Pharmaceutical
Italy-based biopharma Newron Pharmaceuticals was trading 14% higher at lunchtime on Tuesday. 30 April 2024
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio saw its shares plunge 60% to $7.28 by close of trading, despite what it said were positive results for its Alzheimer’s disease (AD) candidate. 30 April 2024
Biotechnology
US biotech Repertoire Immune Medicines has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases. 29 April 2024
Biotechnology
Switzerland’s clinical-stage biotech Addex Therapeutics saw its shares plunge 50% to 0.058 francs this morning, after it reported disappointing trial results for its epilepsy candidate. 29 April 2024
Biotechnology
The European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. 26 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze